Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/rheumatology/keae431 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Systemic lupus erythematosus in a patient with 22q11.2 deletion syndrome: A case report and review of the literature.
Cent Eur J Immunol
November 2024
Department of Rheumatology and Immunology, Hangzhou Normal University Affiliated Hospital, Hangzhou, China.
22q11.2 deletion syndrome (MIM: 192430/188400, ORPHA: 567) is the most common chromosomal microdeletion disorder, caused by a hemizygous microdeletion of 2.5 million base pairs on chromosome 22.
View Article and Find Full Text PDFAlopecia Areata Following the Use of Belimumab in a Patient with Systemic Lupus Erythematosus and Arthritis Who Responded Well to Baricitinib: A Case Report.
Am J Case Rep
December 2024
Department of Medicine, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia.
Article Synopsis
- * A case study of a 54-year-old Saudi woman with SLE revealed that after conventional medication failed, treatment with belimumab improved her condition, but later led to worsening symptoms, including severe hair loss.
- * The subsequent administration of baricitinib after stopping belimumab showed significant improvement in her hair loss and arthritis symptoms, suggesting a need for focused research on specific outcomes in SLE treatment, particularly regarding baricitinib's effectiveness.
A case of rapidly progressive hair loss due to azathioprine, and the prevalence of NUDT15 variants among Japanese patients with autoimmune blistering diseases: A single-center retrospective observational study.
J Dermatol
October 2024
Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Autoimmune blistering diseases (AIBDs), classified into pemphigus and pemphigoid, consist of relatively rare skin disorders caused by autoantibodies that target desmosomal and hemidesmosomal proteins, respectively. Although systemic corticosteroids are used as a first-line treatment for AIBDs, azathioprine is frequently co-administered as a steroid-sparing agent. Azathioprine is metabolized into thioguanine nucleotides (TGNs) which are its major active metabolites.
View Article and Find Full Text PDFAzathioprine related alopecia totalis due to NUDT 15 mutation in a pregnant systemic lupus erythematosus patient with successful obstetric outcome.
Rheumatology (Oxford)
August 2024
Clinical Immunology and Rheumatology Unit, Army Hospital Research & Referral, New Delhi, India.
Background: Alopecia areata (AA) is an autoimmune pathology manifested by loss of hair.
Objective: To evaluate and compare the efficacy and safety of tofacitinib and azathioprine in patients with AA and variants.
Methods: In this double-blind randomized controlled trail (RCT) carried out at the Department of Dermatology, Medical Teaching Institute-Lady Reading Hospital (MTI-LRH), Peshawar, Pakistan, patients aged ≥ 12 years diagnosed with AA, alopecia totalis (AT) or alopecia universalis (AU) with minimum 50% scalp hair loss for a period ≥ 06 years were included.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!